It is well recognized that hyperinsulinemia and INSR signaling are critical determinants responsible for accelerated progression and aggressive phenotype of breast cancer in patients with metabolic disorders (i.e., diabetes, obesity) [2, 3, 6–8]. This evidence concerns the gene INSR and diabetes mellitus.